BEQVEZ is supplied as a clear to slightly opalescent, colorless to slightly brown suspension with each mL containing 1 × 1013 vg.
BEQVEZ is shipped frozen (−100 °C to −60 °C [−148 °F to −76 °F]) in plastic vials with an elastomeric stopper and plastic snap fit cap with an extractable volume of 1 mL.
BEQVEZ is provided as a customized kit containing the number of vials (NDC 0069-0422-01) required to meet dosing requirements for each patient [see Dosage and Administration (2.1)]. The customized kit is accompanied with patient’s specific identifier number (Pfizer Patient Identifier) on the outer carton.
The kit sizes and National Drug Codes (NDC) are provided in Table 6.
Patient Dose Weight (kg) | Total Number of Vials per Kit | NDC Number |
≤75 | 4 | 0069-2004-04 |
>75 to ≤95 | 5 | 0069-2005-05 |
>95 to ≤115 | 6 | 0069-2006-06 |
>115 to ≤135 | 7 | 0069-2007-07 |
BEQVEZ is shipped and delivered frozen between −100 °C to −60 °C (−148 °F to −76 °F) in clear vials.
Upon receipt, immediately place in a freezer between −90 °C to −60 °C (−130 °F to −76 °F).
Store in the original package to avoid direct sunlight and ultraviolet light exposure.
Store upright in the original package. If cartons or individual vials are tipped over or inverted during storage and handling, place the carton or individual vials back in the upright orientation immediately.
Frozen vials in the inner carton will take up to 1 hour to thaw at room temperature (up to 30 °C [86 °F]). Vials may be gently swirled but not shaken or inverted. The total time at room temperature between removing vials from frozen storage until the beginning of dose preparation should be no more than 3 hours. Once thawed, the medicinal product should not be re-frozen and may be stored refrigerated at 2 °C to 8 °C (36 °F to 46 °F) in the inner carton up to 24 hours.
Following dilution in 0.9% sodium chloride with 0.25% HSA, chemical and physical in-use stability has been demonstrated for 24 hours at 2 °C to 30 °C (36 °F to 86 °F).
BEQVEZ is supplied as a clear to slightly opalescent, colorless to slightly brown suspension with each mL containing 1 × 1013 vg.
BEQVEZ is shipped frozen (−100 °C to −60 °C [−148 °F to −76 °F]) in plastic vials with an elastomeric stopper and plastic snap fit cap with an extractable volume of 1 mL.
BEQVEZ is provided as a customized kit containing the number of vials (NDC 0069-0422-01) required to meet dosing requirements for each patient [see Dosage and Administration (2.1)]. The customized kit is accompanied with patient’s specific identifier number (Pfizer Patient Identifier) on the outer carton.
The kit sizes and National Drug Codes (NDC) are provided in Table 6.
Patient Dose Weight (kg) | Total Number of Vials per Kit | NDC Number |
≤75 | 4 | 0069-2004-04 |
>75 to ≤95 | 5 | 0069-2005-05 |
>95 to ≤115 | 6 | 0069-2006-06 |
>115 to ≤135 | 7 | 0069-2007-07 |
BEQVEZ is shipped and delivered frozen between −100 °C to −60 °C (−148 °F to −76 °F) in clear vials.
Upon receipt, immediately place in a freezer between −90 °C to −60 °C (−130 °F to −76 °F).
Store in the original package to avoid direct sunlight and ultraviolet light exposure.
Store upright in the original package. If cartons or individual vials are tipped over or inverted during storage and handling, place the carton or individual vials back in the upright orientation immediately.
Frozen vials in the inner carton will take up to 1 hour to thaw at room temperature (up to 30 °C [86 °F]). Vials may be gently swirled but not shaken or inverted. The total time at room temperature between removing vials from frozen storage until the beginning of dose preparation should be no more than 3 hours. Once thawed, the medicinal product should not be re-frozen and may be stored refrigerated at 2 °C to 8 °C (36 °F to 46 °F) in the inner carton up to 24 hours.
Following dilution in 0.9% sodium chloride with 0.25% HSA, chemical and physical in-use stability has been demonstrated for 24 hours at 2 °C to 30 °C (36 °F to 86 °F).
{{section_body_html_patient}}
Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.
*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.
Submit a medical question for Pfizer prescription products.
Pfizer Safety
To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:
Pfizer Safety Reporting Site*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.
If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.
FDA Medwatch
You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.